

Effects of platelet-rich plasma on mesenchymal stem cells isolated from rat uterus

Polina Vishnyakova^{Corresp., Equal first author, 1, 2}, Daria Artemova^{Equal first author, 1}, Andrey Elchaninov^{1, 3}, Zulfiia Efendieva⁴, Inna Apolikhina^{1, 4}, Gennady Sukhikh¹, Timur Fatkhudinov^{2, 5}

¹ National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of Ministry of Healthcare of Russian Federation, Moscow, Russia

² People's Friendship University of Russia, Moscow, Russia

³ Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia

⁴ I. M. Sechenov First Moscow State Medical University of Ministry of Health of Russia (Sechenov University), Moscow, Russia

⁵ Scientific Research Institute of Human Morphology, Moscow, Russia

Corresponding Author: Polina Vishnyakova
Email address: vpa2002@mail.ru

Background. Platelet-rich plasma (PRP), which represents a valuable source of growth factors, is increasingly applied in regenerative medicine. Recent findings suggest the feasibility of using PRP for the treatment of the infertility caused by refractory thin endometrium. Mesenchymal stem/stromal cells (MSCs) of the endometrium are an essential cellular component responsible for the extracellular matrix remodeling, angiogenesis, cell-to-cell communication and postmenstrual tissue repair. In this study, we examine the effects of autologous PRP on the MSCs isolated from the uterus and compare them with the effects of autologous ordinary plasma (OP) and complete growth medium in rat model.

Methods. MSCs were isolated from the uterine tissues by enzymatic disaggregation. The flow cytometry immunophenotyping of the primary cell cultures was complemented with immunocytochemistry for Ki-67 and vimentin. The ability of MSCs to differentiate in osteo-, chondro- and adipogenic directions was assessed with the use of differentiation-inducing media. The levels of autophagy and apoptosis markers, as well as the levels of matrix metalloproteinase 9 (MMP9) and estrogen receptor α , were assessed by western blotting.

Results. After 24 h incubation, proliferation index of the PRP-treated MSC cultures was significantly higher compared with complete growth medium. PRP elevated production of LC3B protein, an autophagy marker, while OP upregulated the expression of stress-induced protein p53 and extracellular enzyme MMP9. The results indicate practical relevance and validity of PRP usage in the treatment of infertility.

1 Effects of platelet-rich plasma on mesenchymal stem 2 cells isolated from rat uterus

3

4 Vishnyakova Polina ^{1,2##}, Artemova Daria ^{1#}, Elchaninov Andrey ^{1,3}, Efendieva Zulfiia⁴,
5 Apolikhina Inna ^{1,4}, Sukhikh Gennady ¹ and Fatkhudinov Timur ^{2,5}

6 Author affiliations:

7 ¹ National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after
8 Academician V.I. Kulakov of Ministry of Healthcare of Russian Federation, Moscow, Russia

9 ² Peoples' Friendship University of Russia, Moscow, Russia

10 ³ Pirogov Russian National Research Medical University (RNRMU)

11 ⁴ I. M. Sechenov First Moscow State Medical University of Ministry of Health of Russia
12 (Sechenov University), Moscow, Russia

13 ⁵ Scientific Research Institute of Human Morphology, Moscow, Russia

14 # – equal contribution

15

16 Corresponding Author:

17 Polina A. Vishnyakova, PhD

18 Laboratory of regenerative medicine, Research Center for Obstetrics, Gynecology and
19 Perinatology, Ministry of Healthcare of the Russian Federation, Moscow, Russia. Tel:
20 +79150658577.

21 Email: vpa2002@mail.ru or vishnyakovapolina@gmail.com

22

23 Abstract

24

25 **Background.** Platelet-rich plasma (PRP), which represents a valuable source of growth factors,
26 is increasingly applied in regenerative medicine. Recent findings suggest the feasibility of using
27 PRP for the treatment of the infertility caused by refractory thin endometrium. Mesenchymal
28 stem/stromal cells (MSCs) of the endometrium are an essential cellular component responsible
29 for the extracellular matrix remodeling, angiogenesis, cell-to-cell communication, and
30 postmenstrual tissue repair. In this study, we examine the effects of autologous PRP on the
31 MSCs isolated from the uterus and compare them with the effects of autologous ordinary plasma
32 (OP) and complete growth medium in rat model.

33 **Methods.** MSCs were isolated from the uterine tissues by enzymatic disaggregation. The flow
34 cytometry immunophenotyping of the primary cell cultures was complemented with
35 immunocytochemistry for Ki-67 and vimentin. The ability of MSCs to differentiate in osteo-,
36 chondro- and adipogenic directions was assessed with the use of differentiation-inducing media.
37 The levels of autophagy and apoptosis markers, as well as the levels of matrix metalloproteinase
38 9 (MMP9) and estrogen receptor α , were assessed by western blotting.

39 **Results.** After 24 h incubation, proliferation index of the PRP-treated MSC cultures was
40 significantly higher compared with complete growth medium. PRP elevated production of LC3B
41 protein, an autophagy marker, while OP upregulated the expression of stress-induced protein p53
42 and extracellular enzyme MMP9. The results indicate practical relevance and validity of PRP
43 usage in the treatment of infertility.

44

45

46 **Introduction**

47

48 Platelet-rich plasma (PRP) is a term for collected blood plasma with artificially concentrated
49 platelets (Theoret & Stashak, 2014) and correspondingly increased loads of latent growth factors
50 and other active substances. Blood platelets contain three types of granules: dense granules, α -
51 granules and lysosomes (Flaumenhaft & Sharda, 2018); the most abundant are α -granules which
52 contain a number of active substances including chemokines and growth factors (Yun et al.,
53 2016) e.g. platelet-derived growth factors (PDGFs), transforming growth factors (TGFs), insulin-
54 like growth factors (IGFs), vascular endothelial growth factor (VEGF), epidermal growth factor
55 (EGF), fibroblast growth factors (FGFs) (Lubkowska, Dolegowska & Banfi, 2012). PRP is also
56 rich in fibrin, fibronectin and vitronectin (Marx, 2019). PRP as a potential therapeutics for tissue
57 repair was introduced in 1998 by Marx et al. (Marx et al., 1998) who reported enhanced rates of

58 bone formation in the osteoplasty of human mandibular defects upon adding PRP to the milled
59 bone graft. By now, PRP is widely used in cosmetology, dentistry, sports medicine and surgery
60 (Yuksel et al., 2014; Maffulli, 2016; Patel et al., 2016); it can be injected in soft tissues, mixed
61 with a graft, layered, sprayed, or used as a biological membrane (Civinini et al., 2011).
62 Degranulation of the platelets upon the PRP activation promotes fibrinogen cleavage and
63 formation of the gel-like matrix. Main PRP activators used in laboratory practice are calcium,
64 thrombin and collagen (Cavallo et al., 2016; Maffulli, 2016). The most common PRP activator is
65 calcium, which acts faster than collagen but slower than thrombin (Kim & Byeon, 2019). The
66 activation leads to immediate release of growth factors which start to act at the site of PRP
67 administration. The platelets release 70% of their total content of growth factors within 10
68 minutes after PRP activation with CaCl_2 , and the rest 30% are released in the course of 1 hour.
69 Moreover, the activated platelets continue to produce extra amounts of growth factors. As the
70 activated platelets die at about 8 hours after the stimulus, PRP activation should be carried out
71 immediately before the use (Kim & Byeon, 2019).

72 PRP exerts a local stimulating effect on cell growth at the site of administration. The benefits
73 of PRP treatment are currently finding recognition in reproductive technologies. A recent study
74 involved 24 female participants with refractory thin endometrium (5 mm or thinner) and a
75 history of IVF failure: a course of three repeated infusions of PRP into the uterine cavity caused
76 significant improvement in the condition, with, respectively, 60% of and 54% of the patients
77 successfully entering pregnancy and giving birth (Frantz et al., 2020). The effectiveness of PRP
78 for the treatment of the thin endometrium has been previously reported by Zadehmodarres et al.;
79 the study involved 10 female participants with thin endometrium (7 mm or thinner) who received
80 PRP infusions. After two infusions, the thickness of endometrium exceeded 7 mm in all patients,

81 which enabled the frozen-thawed embryo transfer (FET) procedure. As a result, 5 (50%) of the
82 patients successfully entered pregnancy (Zadehmodarres et al., 2017). Coksuer et al. evaluated
83 the PRP treatment of thin endometrium as an alternative to estradiol therapy in patients with a
84 history of three or more failed IVF cycles. The resulting endometrium thickness (respectively, 10
85 and 8 mm on average for the PRP and estradiol groups) enabled FET in all cases. The PRP
86 therapy afforded higher rates of clinical pregnancy and live births (14% vs 6%) against a
87 backdrop of lower occurrence of miscarriages (3% versus 6%) compared with the estradiol
88 therapy (Coksuer, Akdemir & Ulas Barut, 2019). In study of Kim et al., intrauterine
89 administration of the autologous PRP also improved implantation and pregnancy outcomes for
90 the patients with the refractory thin endometrium-associated infertility which indicates profound
91 functional consistency of its effects (Kim et al., 2019).

92 Endometrium is a dynamic structure composed of simple columnar epithelium with uterine
93 glands, and the underlying stroma (Pertschuk, 1990) with blood vessels, nerves, collagen and
94 reticular fibers, and a variety of stromal cells (Aplin, 2018). Isolation of mesenchymal
95 stem/stromal cells (MSCs) from endometrium (Chan, Schwab & Gargett, 2004; Chan & Gargett,
96 2006) allows elucidation of tissue-specific functions and markers of these cells thus opening new
97 prospects of their usage. As actively proliferating cells, MSCs play an important role in the tissue
98 homeostasis of endometrium — they are involved in the extracellular matrix remodeling,
99 angiogenesis, cell-to-cell communication, post-menstrual tissue repair, etc.(Mutlu, Hufnagel &
100 Taylor, 2015; Arutyunyan et al., 2016). Endometrial stromal cells are highly susceptible to the
101 action of PRP (Matsumoto et al., 2005); however, only a few works are devoted to studying of
102 exact mechanisms of PRP action on these cells (Aghajanova et al., 2018). The use of rat
103 endometrial MSCs makes a good model for studying the action of PRP in the perspective of

104 infertility treatment due to the ethical accessibility and sufficient size of the biomaterial which
105 allows to obtain more cells than from human pipe endometrial biopsy (Jang et al., 2017).

106 Experimental animal models are accessible and provide better uniformity of samples. The use
107 of human biomaterial is invariably associated with heterogeneity of anamneses and preliminary
108 treatment regimens, the use of different collection protocols. Moreover, in the cases of thin
109 endometrium, the diagnostic curettage is strongly contraindicated and substituted with pipe
110 biopsies which provide very limited sample volumes insufficient for the comprehensive
111 examination.

112 MSCs isolated from the rat uterus represent an available counterpart to the MSCs of human
113 endometrium. The uterine tissues were preferred to the conventional sources of MSCs (including
114 the red bone marrow, adipose tissue and umbilical cord) because of the significant difference in
115 functional properties of MSCs isolated from different locations in the body. For example, MSCs
116 isolated from adipose tissue show higher proliferation rates and a higher adipogenic
117 differentiation capacity than MSCs isolated from the red bone marrow (Brown et al., 2019). At
118 the same time, the bone marrow-derived MSCs are more prone to osteogenic differentiation,
119 whereas MSCs isolated from muscle tissue show the highest rates of differentiation into
120 myogenic progeny and express myoblastic markers (Brown et al., 2019). Despite the common
121 immunophenotype signatures of MSCs isolated from different tissue sources (they express
122 CD73, CD90, and CD105 and do not express hematopoietic markers CD34 and CD45 at their
123 surface), these cells also exhibit a number of tissue-specific surface markers (Klimczak &
124 Kozłowska, 2016), which implicates the tissue-dependent functional specificity.

125 In this study, we examine the effects of autologous PRP on the MSCs isolated from rat uterus
126 and compare them with the effects of autologous ordinary plasma (OP).

127 **Materials & Methods**

128

129 **Ethical disclosure**

130 The authors state that they have obtained appropriate institutional review board approval or
131 have followed the principles outlined in the Declaration of Helsinki for all human or animal
132 experimental investigations. The study was approved by the Ethical Review Board at the
133 Scientific Research Institute of Human Morphology (Protocol №.15, 9th of December, 2019).

134 **Animals.** The outbred eight-week-old female Sprague-Dawley rats of 250–300 g weight were
135 obtained from the Institute for Bioorganic Chemistry branch animal facilities (Pushchino,
136 Moscow region, Russia). All experimental work involving animals was carried out according to
137 the standards of laboratory practice (National Guidelines No. 267 by Ministry of Healthcare of
138 the Russian Federation, June 1, 2003), and all efforts were made to minimize the suffering. The
139 animals were adapted to the laboratory conditions (23°C, 12 h/12 h light/dark, 50% humidity,
140 and ad libitum access to food and water) for 2 weeks prior to the experiments. In adult female
141 rats, the stage of the estrous cycle was determined by taking a vaginal smear. The smear was
142 stained with methylene blue and the stage was determined by assessment of cellular composition
143 of the smear. The uterus was dissected at the stage of metestrus after the euthanasia in a CO₂-
144 chamber; the blood was collected by puncture from the heart. Animals served only as a source of
145 the uterus and autologous plasma; therefore, no experimental conditions and endpoints were
146 used.

147 **PRP and OP preparation.** The blood was collected in tubes with 2 ml of heparin (5000 IU/ml)
148 and 800 µl of 10% sodium citrate. An average of 6 ml of blood was obtained from one animal.
149 PRP was obtained based on a protocol developed by Yazigi et al. (Yazigi Junior et al., 2015).
150 The blood was centrifuged at 400 g for 10 min, the plasma was collected in a new tube and

151 centrifuged again at 4 °C, 400 g for 10 min. After centrifugation, 70% of the supernatant (the
152 platelet-poor plasma, PPP) was discarded. The remaining fraction PRP, which according to the
153 modern classification belongs to L type (L-PRP), was preserved. The platelet counts were
154 determined on a TC20 Automated Cell Counter (Bio-Rad, USA) and constituted 50×10^6
155 platelets/ml on average. To obtain OP, the blood was centrifuged at 4 °C, 2000 g for 15 min, and
156 the supernatant was collected. The prepared OP and PRP were aliquoted, frozen and stored at -
157 20 °C. Before use, PRP was activated by adding 10% CaCl₂ (10 µl of per 200 µl of PRP)
158 according to the protocol by Messori et al. (Messori et al., 2011)

159 ***The protocol for obtaining MSCs from rat endometrium.*** The primary cell cultures were
160 obtained based on the protocol by De Clercq et al. with modifications (De Clercq, Hennes &
161 Vriens, 2017). The dissected uterus was minced with scissors in Hank's Balanced Salt Solution
162 (HBBS) and transferred into 0.25% trypsin. The tube was incubated at 4 °C for 1 h, then at 22 °C
163 for 1 h, and finally at 37 °C for 15 min with periodical shaking. The supernatant was taken and
164 the solid bulk was transferred to a solution of collagenases type I and type IV in 0.05% trypsin-
165 EDTA solution (collagenase I:collagenase IV:trypsin-EDTA, 1:1:10), incubated at 37 °C for 30
166 min, and passed through a 70 µm cell strainer. The material remaining on the strainer was
167 transferred to a fresh solution of collagenases with 0.05% trypsin-EDTA, incubated at 37 °C for
168 15 min, and passed through a strainer again. The resulting suspension containing the cells of
169 interest was centrifuged at 300 g for 5 min at 22 °C. The pellet was resuspended in HBBS
170 supplemented with 1% FBS, centrifuged again, and resuspended in complete growth medium
171 (DMEM/F-12 supplemented with 10% FBS, L-glutamine and penicillin/streptomycin) for
172 cultivation. The obtained cells were verified for compliance with the minimal criteria for MSCs
173 issued by the International Society for Cellular Therapy (Dominici et al., 2006) (adhesion to

174 untreated plastic, specific profile of surface antigens, and *in vitro* differentiation towards
175 osteogenic, chondrogenic and adipogenic progeny). To assess the effects of PRP and OP on
176 MSCs, the cells were cultured for 24 h in the medium supplemented with 10% PRP and 10% OP,
177 respectively, instead of FBS. Complete growth medium (CGM) with 10% FBS was used as the
178 control.

179 ***Flow cytometry analysis.*** Immunophenotyping of the cells for the surface and intracellular
180 markers was performed upon reaching 80% confluence. The harvested cells were centrifuged at
181 800 g for 10 min, the supernatant was discarded, the cells were fixed in 2% paraformaldehyde
182 for 15 min at room temperature (RT), diluted with 5 ml of PBS, and centrifuged at 1500 g for 10
183 min. The pellet was resuspended in 1 ml of PBS. For immunostaining, 1×10^5 of fixed cells cells
184 were incubated in 100 μ l of Rinsing Solution (Miltenyi Biotec, USA) with primary antibodies to
185 CD90 (ab225, 1/100, Abcam), CD45 (130-107-846, clone REA504, 1/20, Miltenyi Biotec),
186 CD105 (ab107595, 1/100, Abcam), CD34 (PAB18289, 1/100, Abnova) at room temperature for
187 1 h, and subsequently with secondary antibodies — anti-mouse Ig-FITC (ab6785, 1/500, Abcam)
188 or anti-rabbit Ig-PE (sc-3739, 1/100, Santa Cruz) at RT for 1 h in the dark. After the incubation,
189 the cells were washed in PBS, resuspended in 0.5 ml of PBS, and transferred to fresh tubes for
190 the analysis on a FACScan flow cytometer (Becton Dickinson, USA) with the CellQuest
191 software.

192 ***Induced differentiation of MSCs.*** The ability of MSCs to differentiate in osteo-, chondro- and
193 adipogenic directions was assessed at early passages (up to 7). The cells were grown to 70%
194 confluency in CGM, and then the growth medium was replaced with differentiation medium (for
195 differentiation) or CGM (for the controls). Differentiation into adipogenic progeny was
196 accomplished by using StemPro® Adipogenesis Differentiation Kit (Gibco) in the course of 7

197 days. At the end of the differentiation process, the cells were fixed with ethyl alcohol:formalin
198 solution (1:4) for 3 minutes and stained with Sudan III (5.7 mM) for 10 minutes to visualize fat
199 droplets. For osteogenic differentiation, the medium was supplemented with dexamethasone (10⁻⁷
200 M) and ascorbic acid (0.2 mM) in the course of two weeks. At the end, the cells were fixed
201 with 70% alcohol, and for the detection of mineralization sites, the cells were stained with 40
202 mM alizarin red S solution (pH = 4.7) for 5 min. Chondrogenic differentiation was performed by
203 using StemPro® Chondrogenesis Differentiation Kit (Gibco). After two weeks of differentiation,
204 the cells were fixed with 4% formalin for 1 h and for detection of mucopolysaccharides were
205 stained with 1% alcian blue for 24 h. Samples were analyzed using an Axiovert 40 CFL inverted
206 microscope (Zeiss, Germany) using ZEN software (Carl Zeiss, Germany).

207 ***Immunocytochemistry.*** The MSCs were grown on glass coverslips (Fisher Scientific) coated
208 with gelatin and placed in Petri dishes (35 × 10 mm). For immunocytochemistry, the cells were
209 fixed in 2% paraformaldehyde. The coverslips with fixed cells were treated with 0.1% Triton X-
210 100 for 10 min (cell membrane permeabilization) and washed with PBS. Non-specific binding
211 sites were blocked with 1% BSA in PBS with 0.1% Tween-20 for 30 minutes. The coverslips
212 were incubated with antibodies to Ki-67 (ab15580, 1/100, Abcam) or vimentin (ab8978, 1/250,
213 Abcam) at +4 °C for 24 hours. After incubation, the coverslips were washed with PBS and then
214 incubated with the secondary anti-rabbit-PE antibodies (1/200) or anti-rabbit-FITC antibodies
215 (1/200) in the dark at RT for 1 h and subsequently washed with PBS. To stain the nuclei, the
216 coverslips were incubated with DAPI (0.004 mg / ml) at 37 °C for 10 min. Then the coverslips
217 were washed in PBS and mounted in Aqua-Poly Mount (Polysciences, USA). The photographs
218 were made using a Leica DM 4000B fluorescence microscope (Leica Microsystems, Germany)
219 with the LAS AF v.3.1.0 software (Leica Microsystems, Germany).

220 **Western blot assay.** The cells were washed with PBS and lysed in the ice-cold RIPA buffer.
221 The sample was mixed with 2X loading buffer and incubated at 95 °C for 1 minute. The samples
222 were stored at -80 °C until use and heated for 1 min at 95 °C before loading. The proteins were
223 separated by 10–12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
224 and transferred from the gel to PVDF membranes by the semi-wet approach using Trans-Blot®
225 Turbo™ RTA Mini LF PVDF TransferKit (Bio-Rad Laboratories, Inc.). The membranes were
226 blocked with 5% milk in Tris-buffered saline containing 0.1% Tween (TTBS) at RT for 1 h, then
227 stained overnight with primary antibodies to LC3B (1:3000, ab48394, Abcam), Bcl-2 (1:1000,
228 ab32124, Abcam), p53 (1:250, ab90363, Abcam), ER α (1:2000, ab3575, Abcam), MMP-9
229 (1:1000, ab38898, Abcam) and GAPDH (1:500, sc-25778, Santa Cruz) and subsequently with
230 the HRP-conjugated secondary antibodies (1:5000, Bio-Rad Laboratories, Inc.).
231 Chemiluminescent signal developed by using Novex ECL Kit (Invitrogen, USA) was visualized
232 in a C-DiGit® Blot Scanner (LI-COR, USA) using the Image Studio™ Acquisition Software
233 (LI-COR, USA). Figure of uncropped membrane is available in Supplementary information
234 (Fig.S1). The relative protein levels were determined via normalization by GAPDH signals. The
235 bands represent biological replicates (i.e. correspond to different individuals).

236 **Statistical analysis.** Statistical data processing was performed in the GraphPad Prism 8
237 (Software GraphPad Software, USA). The Shapiro-Wilk test was applied to assess the normality
238 of distributions. In the case of normal distribution, one-way ANOVA with the Turkey post-hoc
239 test for multiple comparison was used. In the case of non-normal distribution, the Kruskal-Wallis
240 test with the post-hoc Dunn test was used. The differences were considered statistically
241 significant at $p < 0.05$.

242 **Results**

243

244 **Characterization of the isolated MSCs.** The uterus is a non-classical source of MSCs. Given
245 the wide variability of MSC phenotypes and tissue-specific features (Kwon et al., 2016), the first
246 stage of our study was to show the compliance of rat uterine mesenchymal cell cultures to the
247 established minimal criteria for MSCs, including the immunophenotype and the capability of
248 induced *in vitro* differentiation into different mesenchymal lineages. The obtained cultures of
249 fibroblast-like cells were immunophenotyped by flow cytometry for CD90, CD105, CD45 and
250 CD34. The region of interest was selected by relation of forward and side scattering values in a
251 FSC-SSC dot plot diagram (Figure 1 a) reflecting the size and granularity of the cells,
252 respectively. We gated the major pool of single cell events (R1) excluding debris (Figure 1 a).
253 The peaks of fluorescence were distinctly shifted in histograms for the MSC samples stained
254 specifically with antibodies to CD90 and CD105 compared with the controls stained with
255 secondary antibodies only (Figure 1 b, green curve). We found that 72.7% of the cells were
256 positive for CD90 and 31.8% of the cells were positive for CD105, which indicated
257 correspondence of the obtained cultures to the CD90+CD105+ phenotype. Interestingly, 3.1%
258 and 20.1% of the cells were positive for CD45 and CD34, respectively. To further confirm the
259 compliance, we stained the cultures for vimentin. The immunocytochemical assay revealed the
260 presence of vimentin protein in 100% of the cells (Figure 1 c).

261 We promoted differentiation of the cell cultures into adipogenic, osteogenic and chondrogenic
262 lineages by using specific combinations of inducers. The adipogenic differentiation was
263 identified by formation of lipid droplets revealed by staining with Sudan III (Figure 1 d, left
264 panel). During the osteogenic differentiation, the cells formed characteristic conglomerates, with
265 the foci of calcification revealed by alizarin red staining (Figure 1 d, central panel). During the
266 chondrogenic differentiation, conglomerates were also formed by the cells, and the

267 mucopolysaccharide production was revealed by staining with alcian blue (Figure 1 d, right
268 panel).

269 **Effects of autologous PRP and OP on cell proliferation and cell death.** Effects of
270 autologous PRP and OP on the rat uterine MSC cultures were evaluated after 24 h incubation of
271 the cells in a medium containing 10% PRP or 10% OP instead of FBS. Accordingly, complete
272 growth medium (CGM) with 10% FBS was used as a control. Proliferation was assessed by
273 immunocytochemical staining for Ki-67 following the incubation (Figure 2 a). The percentage of
274 Ki-67 positive nuclei divided by the total number of nuclei (proliferation index) was 18.1% for
275 CGM, 41.9% for PRP, and 21.7% for OP (Figure 2 b). For PRP, the differences were statistically
276 significant ($p = 0.04$).

277 To evaluate the activation or inhibition of apoptosis, we analyzed the production of the stress-
278 induced protein p53 and the anti-apoptotic protein Bcl-2. The p53 protein levels were
279 significantly higher in the cells exposed to OP ($p = 0.03$), as compared with the control (Figure 2
280 c, d). After PRP exposure p53 production level did not change. Relative levels of Bcl-2
281 production did not differ among the studied groups (Figure 2 c, e).

282 Autophagy was assessed by the level of production of the autophagy marker LC3B. Western
283 blot analysis revealed elevated production of LC3B protein in the cells exposed to autologous
284 PRP, as compared with the control (CGM, Figure 2 c, f); the observed effect was statistically
285 significant.

286 **Endometrium receptivity: effects of autologous PRP and OP on the matrix**
287 **metalloproteinase 9 (MMP9) and estrogen receptor α (ER α) production.** Zinc-
288 metalloproteinase MMP9 participates in the extracellular matrix remodeling. We estimated
289 potential invasiveness of MSCs as a correlate of MMP9 production. Although elevated levels of

290 MMP9 production were observed in both OP and PRP groups compared to CGM, only in the OP
291 treated cultures the MMP9 upregulation was significant ($p = 0.03$, Figure 3 a, b). In addition, we
292 compared the levels of ER α , which can be partially associated with endometrial receptivity
293 (Figure 3 c, d). Despite the elevated ER α levels in the PRP and OP treated cultures, the
294 differences were not significant.

295 **Discussion**

296 Administration of PRP for the treatment of thin endometrium has been already introduced to
297 clinical practice in a pilot study by Kim et al. aimed at increasing the endometrium thickness and
298 accordingly the probability of implantation (Kim et al., 2019). However, the exact mechanism of
299 the positive effect of PRP on the endometrium thickness remains obscure. In this study, we
300 attempt to identify signaling pathways activated in the multipotent stromal cells of endometrium
301 under the influence of autologous PRP by using rat endometrium as a model. Endometrial MSCs
302 play a key role in the stroma: they participate in the regeneration of the functional layer of the
303 endometrium due to the presence of receptors for sex hormones and the ability for extracellular
304 matrix remodeling (Mutlu, Hufnagel & Taylor, 2015). These features emphasize the importance
305 of MSCs for the receptivity of endometrium during the implantation period. We isolated primary
306 cultures of stromal cells from the rat uterus and proved that these cells were essentially MSCs by
307 their ability to differentiate in adipogenic, osteogenic and chondrogenic directions *in vitro*.
308 Phenotypic profiles of the isolated primary cultures were compliant with the
309 CD90+CD105+Vimentin+CD45-CD34- profiles established for MSCs. The presence of cells
310 positive for the CD45 and CD34 markers can be explained by small admixture of hematopoietic
311 cells and high vascularization of the endometrial stroma. Considering a precedent of the 81%
312 CD34- for synovial fluid-derived MSCs and 97.5% CD34- for synovial membrane-derived

313 MSCs cultures classified as CD34 negative, we classify the obtained cultures as CD45 and CD34
314 negative. The percentage of cells positive for CD105 seems lower than it was expected; however,
315 the published evidence indicates substantial variability of this parameter for MSCs isolated from
316 different tissue sources (Ponnaiyan & Jegadeesan, 2014).

317 In the experiments with plasma treatment, the obtained MSCs were incubated for 24 h in the
318 control medium (the DMEM/F-12 based complete growth medium with 10% FBS) or the
319 medium supplemented with autologous 10% PRP or 10% OP instead of FBS. We observed
320 increased proliferation rates of MSCs under the influence of PRP compared with the influence of
321 FBS. This observation indicates mitogenic effects of PRP on stromal cells. We also studied the
322 protein production levels for the established markers of apoptosis and autophagy. The stress-
323 induced protein p53 is a transcription factor that regulates cell cycle and acts as a tumor
324 suppressor (Labuschagne, Zani & Vousden, 2018). An important function of p53 is to prevent
325 the accumulation of DNA damage. In the case of damage to cellular DNA, p53 promotes cell
326 cycle arrest and triggers the emergency DNA repair systems; in the case of extensive DNA
327 damage, p53 triggers apoptosis (Wang, Simpson & Brown, 2015). We show that OP promotes
328 increased production of p53 protein by stromal cells, revealing a certain degree of cellular stress
329 associated with the OP treatment. At the same time, both PRP and OP have no effects on the
330 levels of the anti-apoptotic Bcl-2 protein production by MSCs. Bcl-2 is anti-apoptotic protein
331 localized on the outer mitochondrial membrane, as well as the membranes of nuclear envelope
332 and endoplasmic reticulum (Delbridge et al., 2016). Apparently, Bcl-2 activation is not involved
333 in the effects of PRP and OP.

334 We used LC3B as an autophagy marker — this protein is involved in the biogenesis of
335 autophagosomes (Barth, Glick & Macleod, 2010). Upon binding to the membrane, LC3

336 conjugates with phosphatidylethanolamine lipid (Tanida, Ueno & Kominami, 2008). After the
337 autophagosome formation, LC3-II located in the outer layer is released into the cytosol, while
338 LC3-II located in the inner layer is exposed to hydrolases. LC3B-II is conventionally used as a
339 marker of autophagosomal activity. We observed excessive production of LC3B in MSCs after
340 the exposure to PRP. This observation suggests that PRP contribute to self-renewal of the
341 endometrial stromal cells by enhancing autophagy. The rapamycin-induced autophagy was
342 shown to enhance the viability of MSCs, while shRNA-mediated knockdown of the autophagy-
343 associated genes decreased their viability (Molaei et al., 2015; Jakovljevic et al., 2018). The
344 decreased autophagy levels are currently considered as one of the mechanisms underlying the
345 aging of MSCs (Fafián-Labora, Morente-López & Arufe, 2019).

346 Endometrial receptivity results from a combination of different characteristics of the
347 endometrium responsible for the ability to promote implantation. One of the indicators of
348 endometrial receptivity is the level of ER α , as it mediates the action of estrogens preparing the
349 endometrium for implantation by increasing its thickness via the increase in the rates of cell
350 proliferation. In clinical practice, the level of production of ER α can be evaluated by staining of
351 endometrial cells with antibodies to ER α (Glasser et al., 2002), which is expressed by several
352 subpopulations of endometrial stromal cells including MSCs (Zhou et al., 2001). We therefore
353 employed ER α as a marker reflecting the conditional receptivity of endometrium in our model.
354 We observed no significant differences in the level of ER α production upon exposure of the
355 MSCs to PRP or OP, which may indicate that the beneficial effects of these agents are estrogen-
356 independent. However, this finding should be verified on larger samples to exclude individual
357 variations in the estrogen dependence of the plasma treatment effects.

358 Apart from sensitivity of the endometrium to the action of hormones, it should be susceptible
359 and supportive to the trophoblast invasion. The trophoblast cells bind to the endometrium,
360 proliferate and penetrate deep into the stroma to come into contact with the maternal blood
361 (Bischof, Meisser & Campana, 2000). Progressive remodeling of the extracellular matrix is a
362 hallmark of this process (Bischof, Meisser & Campana, 2002). Expression of matrix
363 metalloproteinases, observed not only in the trophoblast but also in the endometrial stromal cells,
364 provides effective support to the trophoblast invasion (Bischof, Meisser & Campana, 2002). In
365 this study, we used MMP9 production as an indicator of the MSC capacity for extracellular
366 matrix remodeling, which is an important parameter of morphogenetic plasticity and receptivity
367 of the endometrium. We demonstrated an increase in the MMP9 production specifically
368 facilitated by OP as compared to CGM.

369 In general, the obtained results indicate stimulatory effects of PRP on the endometrium, as
370 indicated by behavior of MSCs isolated from it. Some other studies also indicate that PRP enhances
371 cell proliferation and differentiation in the uterus (Aghajanova et al., 2018; Etulain et al., 2018).
372 Intrauterine administration of PRP to the rats with damaged endometrium enhanced proliferation
373 thus promoting tissue repair and also reducing fibrosis (Jang et al., 2017).

374 In the study by Kim and et al. the therapeutic effect of PRP in the treatment of Asherman's
375 syndrome on a mouse model was demonstrated (Kim et al., 2020). Asherman's syndrome is
376 characterized by formation of adhesions and fibrotic lesions inside the uterus. Injections of human
377 PRP at the sites of damage reduced the degree of fibrosis and promoted the recovery. It was shown
378 that after PRP therapy implantation potential substantially increased and 83.3% of PRP-treated
379 mice gave birth to live offspring compared to the 0.0% in the control group.

380 The receptivity of endometrium strongly depends on the inflammatory status and favorable
381 antimicrobial conditions. Pronounced anti-inflammatory effects of PRP on the endometrium in
382 horses were demonstrated by Reghini et al. (Reghini et al., 2016). Uterine infusions of PRP to
383 mares with chronic endometritis significantly reduced the signs of neutrophilic infiltration and the
384 volume of intrauterine fluid accumulation as observed at 24 h after the treatment (Reghini et al.,
385 2016). The mechanisms of PRP action on the endometrial cells are still disputable and apparently
386 involve anti-inflammatory and pro-proliferative signaling.

387 The effects of OP on endometrium are notably understudied. In our experiments, OP induced
388 up-regulation of the p53 and MMP9 protein expression so the beneficial effects of OP are less
389 pronounced. The growth factors released from the PRP activated platelets stimulate proliferation
390 of endometrial cells and enhance autophagy which indicates the advantages of PRP as a
391 treatment agent for the endometrial dysfunction.

392 **Conclusions**

393 The use of modified blood plasma for clinical applications is expanding. This study evaluates
394 the effects of the autologous platelet-rich plasma (PRP) and ordinary plasma (OP) on tissue-
395 specific MSCs from rat endometrium. Exposure to PRP enhances proliferation of the uterine
396 MSCs with a significant increase in autophagy. Exposure to OP increased the production of the
397 stress-induced protein p53 and extracellular enzyme MMP9. The results indicate the potency of
398 PRP for the treatment of infertility, particularly for the management of thin endometrium.
399 Understanding of molecular pathways mediating the beneficial effects of PRP will expand the
400 range of PRP applications.

401

402 **Acknowledgements**

403 Special thanks to Natalia Usman for her help with proofreading of the manuscript.

404 **References**

- 405 Aghajanova L, Houshdaran S, Balayan S, Manvelyan E, Irwin JC, Huddleston HG,
406 Giudice LC. 2018. In vitro evidence that platelet-rich plasma stimulates cellular
407 processes involved in endometrial regeneration. *Journal of Assisted Reproduction
408 and Genetics* 35:757–770. DOI: 10.1007/s10815-018-1130-8.
- 409 Aplin J. 2018. Uterus-endometrium. In: *Encyclopedia of Reproduction*. Elsevier, 326–
410 332. DOI: 10.1016/B978-0-12-801238-3.64654-8.
- 411 Arutyunyan I V., Fatkhudinov TH, El'chaninov A V., Makarov A V., Kananykhina EY,
412 Usman NY, Raimova ES, Goldshtein D V., Bol'shakova GB. 2016. Effect of
413 Endothelial Cells on Angiogenic Properties of Multipotent Stromal Cells from the
414 Umbilical Cord during Angiogenesis Modeling in the Basement Membrane Matrix.
415 *Bulletin of Experimental Biology and Medicine* 160:575–582. DOI: 10.1007/s10517-
416 016-3221-9.
- 417 Barth S, Glick D, Macleod KF. 2010. Autophagy: assays and artifacts. *The Journal of
418 pathology* 221:117–24. DOI: 10.1002/path.2694.
- 419 Bischof P, Meisser A, Campana A. 2000. Mechanisms of endometrial control of
420 trophoblast invasion. *Journal of reproduction and fertility. Supplement* 55:65–71.
- 421 Bischof P, Meisser A, Campana A. 2002. Control of MMP-9 expression at the maternal-
422 fetal interface. In: *Journal of Reproductive Immunology*. Elsevier, 3–10. DOI:
423 10.1016/S0165-0378(01)00142-5.
- 424 Brown C, McKee C, Bakshi S, Walker K, Hakman E, Halassy S, Svinarich D, Dodds R,
425 Govind CK, Chaudhry GR. 2019. Mesenchymal stem cells: Cell therapy and
426 regeneration potential. *Journal of Tissue Engineering and Regenerative Medicine*
427 13:1738–1755. DOI: 10.1002/term.2914.
- 428 Cavallo C, Roffi A, Grigolo B, Mariani E, Pratelli L, Merli G, Kon E, Marcacci M, Filardo
429 G. 2016. Platelet-Rich Plasma: The Choice of Activation Method Affects the
430 Release of Bioactive Molecules. *BioMed Research International* 2016. DOI:
431 10.1155/2016/6591717.
- 432 Chan RWS, Gargett CE. 2006. Identification of Label-Retaining Cells in Mouse
433 Endometrium. *STEM CELLS* 24:1529–1538. DOI: 10.1634/stemcells.2005-0411.
- 434 Chan RWS, Schwab KE, Gargett CE. 2004. Clonogenicity of Human Endometrial
435 Epithelial and Stromal Cells1. *Biology of Reproduction* 70:1738–1750. DOI:
436 10.1095/biolreprod.103.024109.
- 437 Civinini R, Macera A, Nistri L, Redl B, Innocenti M. 2011. The use of autologous blood-
438 derived growth factors in bone regeneration. *Clinical Cases in Mineral and Bone
439 Metabolism* 8:25–31.
- 440 De Clercq K, Hennes A, Vriens J. 2017. Isolation of mouse endometrial epithelial and
441 stromal cells for in Vitro decidualization. *Journal of Visualized Experiments* 2017.
442 DOI: 10.3791/55168.
- 443 Coksuer H, Akdemir Y, Ulas Barut M. 2019. Improved in vitro fertilization success and
444 pregnancy outcome with autologous platelet-rich plasma treatment in unexplained
445 infertility patients that had repeated implantation failure history. *Gynecological
446 Endocrinology* 35:815–818. DOI: 10.1080/09513590.2019.1597344.
- 447 Delbridge ARD, Grabow S, Strasser A, Vaux DL. 2016. Thirty years of BCL-2:
448 Translating cell death discoveries into novel cancer therapies. *Nature Reviews
449 Cancer* 16:99–109. DOI: 10.1038/nrc.2015.17.

- 450 Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, Deans
451 RJ, Keating A, Prockop DJ, Horwitz EM. 2006. Minimal criteria for defining
452 multipotent mesenchymal stromal cells. The International Society for Cellular
453 Therapy position statement. *Cytotherapy* 8:315–317. DOI:
454 10.1080/14653240600855905.
- 455 Etulain J, Mena HA, Meiss RP, Frechtel G, Gutt S, Negrotto S, Schattner M. 2018. An
456 optimised protocol for platelet-rich plasma preparation to improve its angiogenic
457 and regenerative properties. *Scientific Reports* 8:1–15. DOI: 10.1038/s41598-018-
458 19419-6.
- 459 Fafián-Labora JA, Morente-López M, Arufe MC. 2019. Effect of aging on behaviour of
460 mesenchymal stem cells. *World Journal of Stem Cells* 11:337–346. DOI:
461 10.4252/wjsc.v11.i6.337.
- 462 Flaumenhaft R, Sharda A. 2018. The life cycle of platelet granules. *F1000Research* 7.
463 DOI: 10.12688/f1000research.13283.1.
- 464 Frantz N, Ferreira M, Kulmann MI, Frantz G, Bos-Mikich A, Oliveira R. 2020. Platelet-
465 Rich plasma as an effective alternative approach for improving endometrial
466 receptivity - a clinical retrospective study. *JBRA Assisted Reproduction*. DOI:
467 10.5935/1518-0557.20200026.
- 468 Glasser SR, Aplin JD, Giudice LC, Tabibzadeh S. 2002. *The endometrium*. Taylor &
469 Francis.
- 470 Jakovljevic J, Harrell CR, Fellabaum C, Arsenijevic A, Jovicic N, Volarevic V. 2018.
471 Modulation of autophagy as new approach in mesenchymal stem cell-based
472 therapy. *Biomedicine and Pharmacotherapy* 104:404–410. DOI:
473 10.1016/j.biopha.2018.05.061.
- 474 Jang HY, Myoung SM, Choe JM, Kim T, Cheon YP, Kim YM, Park H. 2017. Effects of
475 autologous platelet-rich plasma on regeneration of damaged endometrium in
476 female rats. *Yonsei Medical Journal* 58:1195–1203. DOI:
477 10.3349/ymj.2017.58.6.1195.
- 478 Kim MH, Byeon HS. 2019. Review for good platelet-rich plasma procedure in cosmetic
479 dermatology and surgery. *Journal of Cosmetic Medicine* 3:1–13. DOI:
480 10.25056/jcm.2019.3.1.1.
- 481 Kim JH, Park M, Paek JY, Lee WS, Song H, Lyu SW. 2020. Intrauterine Infusion of
482 Human Platelet-Rich Plasma Improves Endometrial Regeneration and Pregnancy
483 Outcomes in a Murine Model of Asherman's Syndrome. *Frontiers in Physiology*.
484 DOI: 10.3389/fphys.2020.00105.
- 485 Kim H, Shin JE, Koo HS, Kwon H, Choi DH, Kim JH. 2019. Effect of autologous platelet-
486 rich plasma treatment on refractory thin endometrium during the frozen embryo
487 transfer cycle: A pilot study. *Frontiers in Endocrinology* 10. DOI:
488 10.3389/fendo.2019.00061.
- 489 Klimczak A, Kozłowska U. 2016. Mesenchymal stromal cells and tissue-specific
490 progenitor cells: Their role in tissue homeostasis. *Stem Cells International*. DOI:
491 10.1155/2016/4285215.
- 492 Kwon A, Kim Y, Kim M, Kim J, Choi H, Jekarl DW, Lee S, Kim JM, Shin JC, Park IY.
493 2016. Tissue-specific differentiation potency of mesenchymal stromal cells from
494 perinatal tissues. *Scientific Reports*. DOI: 10.1038/srep23544.
- 495 Labuschagne CF, Zani F, Vousden KH. 2018. Control of metabolism by p53 – Cancer

- 496 and beyond. *Biochimica et Biophysica Acta - Reviews on Cancer* 1870:32–42. DOI:
497 10.1016/j.bbcan.2018.06.001.
- 498 Lee D-H, Sonn CH, Han S-B, Oh Y, Lee K-M, Lee S-H. 2012. Synovial fluid CD34–
499 CD44+ CD90+ mesenchymal stem cell levels are associated with the severity of
500 primary knee osteoarthritis. *Osteoarthritis and Cartilage* 20:106–109. DOI:
501 10.1016/j.joca.2011.11.010.
- 502 Lubkowska A, Dolegowska B, Banfi G. 2012. Growth factor content in PRP and their
503 applicability in medicine. *Journal of biological regulators and homeostatic agents*.
504 Maffulli N. 2016. *Platelet rich plasma in musculoskeletal practice*. DOI: 10.1007/978-1-
505 4471-7271-0.
- 506 Marx RE. 2019. In Situ Tissue Engineering. In: Melville J, Shum J, Young S, Wong M
507 eds. *Regenerative Strategies for Maxillary and Mandibular Reconstruction*.
508 Springer International Publishing, 73–86. DOI: 10.1007/978-3-319-93668-0_7.
- 509 Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. 1998.
510 Platelet-rich plasma: Growth factor enhancement for bone grafts. *Oral Surgery,*
511 *Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics*. DOI:
512 10.1016/S1079-2104(98)90029-4.
- 513 Matsumoto H, Nasu K, Nishida M, Ito H, Bing S, Miyakawa I. 2005. Regulation of
514 Proliferation, Motility, and Contractility of Human Endometrial Stromal Cells by
515 Platelet-Derived Growth Factor. *The Journal of Clinical Endocrinology &*
516 *Metabolism* 90:3560–3567. DOI: 10.1210/jc.2004-1918.
- 517 Messora MR, Nagata MJH, Furlaneto FAC, Dornelles4 RCM, Bomfim SRM, Deliberador
518 TM, Garcia VG, Bosco AF. 2011. A standardized research protocol for platelet- rich
519 plasma (PRP) preparation in rats. *RSBO Revista Sul-Brasileira de Odontologia*.
- 520 Molaei S, Roudkenar MH, Amiri F, Harati MD, Bahadori M, Jaleh F, Jalili MA,
521 Roushandeh AM. 2015. Down-regulation of the autophagy gene, ATG7, protects
522 bone marrow-derived mesenchymal stem cells from stressful conditions. *Blood*
523 *Research* 50:80–86. DOI: 10.5045/br.2015.50.2.80.
- 524 Mutlu L, Hufnagel D, Taylor HS. 2015. The Endometrium as a Source of Mesenchymal
525 Stem Cells for Regenerative Medicine1. *Biology of Reproduction* 92. DOI:
526 10.1095/biolreprod.114.126771.
- 527 Patel AN, Selzman CH, Kumpati GS, McKellar SH, Bull DA. 2016. Evaluation of
528 autologous platelet rich plasma for cardiac surgery: Outcome analysis of 2000
529 patients. *Journal of Cardiothoracic Surgery* 11. DOI: 10.1186/s13019-016-0452-9.
- 530 Pertschuk LP. 1990. *Immunocytochemistry for steroid receptors*. CRC Press.
- 531 Ponnaiyan D, Jegadeesan V. 2014. Comparison of phenotype and differentiation
532 marker gene expression profiles in human dental pulp and bone marrow
533 mesenchymal stem cells. *European Journal of Dentistry* 8:307–313. DOI:
534 10.4103/1305-7456.137631.
- 535 Reghini MFS, Ramires Neto C, Segabinazzi LG, Castro Chaves MMB, Dell’Aqua C de
536 PF, Bussiére MCC, Dell’Aqua JA, Papa FO, Alvarenga MA. 2016. Inflammatory
537 response in chronic degenerative endometritis mares treated with platelet-rich
538 plasma. *Theriogenology* 86:516–522. DOI: 10.1016/j.theriogenology.2016.01.029.
- 539 Tanida I, Ueno T, Kominami E. 2008. LC3 and Autophagy. In: Deretic V ed.
540 *Autophagosome and Phagosome*. Totowa, NJ: Humana Press, 77–88. DOI:
541 10.1007/978-1-59745-157-4_4.

- 542 Theoret CL, Stashak TS. 2014. Integumentary System: Wound Healing, Management,
543 and Reconstruction. In: Orsini J, Divers T eds. *Equine Emergencies*. Elsevier Inc.,
544 238–267. DOI: 10.1016/b978-1-4557-0892-5.00019-2.
- 545 Wang X, Simpson ER, Brown KA. 2015. p53: Protection against tumor growth beyond
546 effects on cell cycle and apoptosis. *Cancer Research* 75:5001–5007. DOI:
547 10.1158/0008-5472.CAN-15-0563.
- 548 Yazigi Junior JA, dos Santos JBG, Xavier BR, Fernandes M, Valente SG, Leite VM.
549 2015. Quantification of platelets obtained by different centrifugation protocols in
550 SHR rats. *Revista Brasileira de Ortopedia (English Edition)* 50:729–738. DOI:
551 10.1016/j.rboe.2015.10.008.
- 552 Yuksel EP, Sahin G, Aydin F, Senturk N, Turanli AY. 2014. Evaluation of effects of
553 platelet-rich plasma on human facial skin. *Journal of Cosmetic and Laser Therapy*
554 16:206–208. DOI: 10.3109/14764172.2014.949274.
- 555 Yun SH, Sim EH, Goh RY, Park JI, Han JY. 2016. Platelet activation: The mechanisms
556 and potential biomarkers. *BioMed Research International*. DOI:
557 10.1155/2016/9060143.
- 558 Zadehmodarres S, Salehpour S, Saharkhiz N, Nazari L. 2017. Treatment of thin
559 endometrium with autologous platelet-rich plasma: A pilot study. *Jornal Brasileiro*
560 *de Reproducao Assistida* 21:54–56. DOI: 10.5935/1518-0557.20170013.
- 561 Zhou S, Zilberman Y, Wassermann K, Bain SD, Sadovsky Y, Gazit D. 2001. Estrogen
562 modulates estrogen receptor α and β expression, osteogenic activity, and
563 apoptosis in mesenchymal stem cells (MSCs) of osteoporotic mice. *Journal of*
564 *Cellular Biochemistry* 81:144–155. DOI: 10.1002/jcb.1096.
- 565

Figure 1

Characterization of the mesenchymal cell cultures isolated from rat uterus.

Flow cytometry analysis: a - representative forward and side scattering dot plot with the region of interest (R1). The percentages of CD90, CD105, CD45 and CD34 positive cells in R1 are indicated (b). Green curve corresponds to the control (stained with secondary antibodies only). Anti-vimentin staining (c): upper image - negative control (secondary antibodies only); lower image - immunocytochemistry with anti-vimentin antibodies (red) and the nuclei counterstained with DAPI (blue). Bars, 20 μm . Induced cell differentiation assay (d): adipogenic differentiation revealed by Sudan III staining, osteogenic differentiation revealed by alizarin red staining, and chondrogenic differentiation revealed by alcian blue staining. Upper panel - the non-induced control cells, bottom panel - cells after the induced differentiation. Bars, 50 μm . One experimental block is marked by a dotted line.




Figure 2

The assessment of cell viability and cell death after the 24 h incubation of rat uterine MSCs with complete growth medium (CGM), platelet-rich plasma (PRP), or ordinary plasma (OP).

Immunocytochemical staining (a) for Ki-67 (green) after 24 h exposure of the MSC cultures to the CGM (left), PRP (central) and OP (right); the nuclei were counterstained with DAPI (blue). Bars, 20 μm . b - proliferation index calculated as the number of Ki-67 positive nuclei divided by the total number of nuclei. * - $p < 0.05$ vs CGM. c -representative western blot membranes with the proteins isolated from MSCs after 24 h incubation with the studied agents, stained with p53, Bcl-2, LC3B and GAPDH specific antibodies. Relative protein levels of p53 (d), Bcl-2 (e) and LC3B (f), normalized by GAPDH level. * - $p < 0.05$ vs CGM group. One experimental block is marked by a dotted line.




Figure 3

Western blot membrane stained with MMP9 and ER α antibodies.

A representative western blot membrane with the proteins isolated from MSCs after 24 h incubation with complete growth medium (CGM), platelet-rich plasma (PRP) and ordinary plasma (OP), stained with MMP9 (a), ER α (c) and GAPDH specific antibodies. Relative protein levels of MMP9 (b) and ER α (d), normalized by GAPDH level. * - $p < 0.05$ vs CGM group.

